Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
4 studies found for:    19179301 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
Conditions: Breast Cancer;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions: Drug: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: radiation therapy;   Procedure: umbilical cord blood transplantation
2 Active, not recruiting Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Conditions: Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma;   Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine;   Drug: mycophenolate mofetil;   Procedure: stem cell transplantation;   Radiation: total body irradiation;   Drug: filgrastim
3 Recruiting Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
Conditions: Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: Fludarabine;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total body irradiation;   Drug: Sirolimus
4 Recruiting Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia
Condition: Precursor Cell Lymphoblastic Leukemia-Lymphoma
Intervention: Drug: Rituximab+mVPDL

Study has passed its completion date and status has not been verified in more than two years.